Drug Type Small molecule drug |
Synonyms O-GlcNAcase inhibitor(Eli Lilly & Co.), LY 3372689, LY-3372689 + [1] |
Action inhibitors |
Mechanism Beta-N-acetylhexosaminidase inhibitors, OGA inhibitors(Protein O-GlcNAcase inhibitors), Peptide aggregation inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H22FN5O3S |
InChIKeyFRVXHWNHGWUTQO-CABZTGNLSA-N |
CAS Registry2241514-56-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 2 | United States | 16 Sep 2021 | |
Alzheimer Disease | Phase 2 | Japan | 16 Sep 2021 | |
Alzheimer Disease | Phase 2 | Australia | 16 Sep 2021 | |
Alzheimer Disease | Phase 2 | Canada | 16 Sep 2021 | |
Alzheimer Disease | Phase 2 | Poland | 16 Sep 2021 |
Not Applicable | - | - | huktixymsh(btxkpgpodk) = nxajqpbaqh fhztrzvqzd (qafhzzxjud ) | - | 31 Dec 2021 | ||
huktixymsh(btxkpgpodk) = sqkwqvdciv fhztrzvqzd (qafhzzxjud ) | |||||||
Phase 1 | - | - | qpelvabkru(xgmmgfxyiv) = LY3372689 was generally well tolerated up to the highest dose in each study, and no serious AE were reported. In the SAD, 40 treatment-emergent AEs (TEAEs) were reported, which were mostly mild in severity. The most common TEAEs were headache, nausea, pain in extremity, pain of skin, vessel puncture site pain, and limb discomfort. In the MAD, 42 TEAEs were reported, all of which were mild in severity. The most reported TEAE was headache. In both studies, there were no clinically significant changes in safety laboratories, including markers of inflammation, muscle injury, hormones and hepatoxicity. afbksutyyi (kvrcpkylqq ) | - | 31 Dec 2021 | ||
Phase 1 | - | 23 | qhvexywaik(wqrpgjyjuf) = jflyzsfgow dldjagsotm (qrstuozfnc ) | Positive | 07 Dec 2020 |